Brazil’s health regulator, Anvisa, has authorized clinical research on Vivaxin, a Brazil-developed candidate vaccine targeting Plasmodium vivax malaria. The agency announced the authorization on October 13, 2026, saying the project would enter its first phase of testing in humans.

The decision allows research to begin; it does not authorize Vivaxin for sale, public vaccination or any other routine use. Nor does it establish that the candidate prevents malaria or is clinically effective.

What happened

The underlying regulatory measure, Resolution-RE No. 3,956, was dated October 6 and published in Brazil’s official gazette, the Diário Oficial da União, on October 7, 2026. It approved petitions related to Vivaxin’s clinical-development dossier and its clinical-research process.

Anvisa’s October 13 explanatory notice described Vivaxin as entering phase 1, the first stage of human testing. The candidate was developed by CTVacinas at the Federal University of Minas Gerais, known as UFMG. The project has reported collaboration from the University of São Paulo, USP, and the company Cristália.

The regulator describes the planned study as randomized, double-blind and placebo-controlled. Its purpose is to assess safety and immunogenicity, including reactions following intramuscular administration. Immunogenicity refers to the immune response generated by a candidate product; measuring it in this study is not the same as demonstrating protection against disease.

Why it matters

The authorization is a regulatory milestone for a candidate developed in Brazil because it moves the project from pre-human research into a controlled clinical setting. Anvisa has described Vivaxin as the first Brazil-developed malaria-vaccine candidate to enter human trials.

That distinction is important. A phase 1 authorization permits a defined research protocol, rather than confirming a vaccine’s effectiveness or granting a marketing authorization. The study is designed principally to examine safety and immune response in a limited group of volunteers. Further research and regulatory steps would be needed before any finding on prevention or public use could be established.

For readers outside Brazil, the case also illustrates the difference between a regulator authorizing a clinical trial and a regulator approving a medical product. In this instance, Anvisa has allowed investigators to test Vivaxin under the authorized research process; it has not endorsed it as a proven vaccine.

By the numbers

The bigger picture

Vivaxin is aimed specifically at Plasmodium vivax malaria. The scope of the authorization is limited to the clinical-development and clinical-research petitions covered by the resolution and the phase 1 protocol described by Anvisa.

The trial’s double-blind and placebo-controlled design means that the study is structured to compare outcomes without participants and relevant study personnel knowing which intervention a participant has received during the blinded period. Anvisa says the work will assess safety and immunogenicity, including reactions after intramuscular administration.

Such design features define how the first human study is to be conducted, not its eventual results. No trial findings were included in the authorization announcement, and the regulator’s action does not make a determination on whether Vivaxin prevents malaria.

What happens next

The planned recruitment will take place through the clinical-research center at UFMG Hospital das Clínicas. Eligible volunteers are healthy adults aged 18 to 59 who have not previously had malaria.

The known next step is therefore the conduct of the authorized phase 1 study and its safety and immunogenicity assessment. The verified information does not provide a timetable for recruitment, results, later-stage trials or a possible application for public use. Any future authorization to market or deploy Vivaxin would be separate from the clinical-research authorization now granted.